Intravenous Infusions Plc (GHSE: IIL)
Health Care · Pharmaceuticals · GH
GH₵0.65
+41.30% today · +1200.0% 1Y
Intravenous Infusions Plc (GHSE: IIL) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $16.11M.
Over the last twelve months the share price has gained 1200.0%, trading between 0.05 and 0.86.
Tweenvest scores Intravenous Infusions Plc across four factors: quality 54/100, value 70/100, growth 0/100. Its strongest factor is value.
IIL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $16.11M
- Revenue (TTM)
- $574.89K
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- -0.57
- 52-week high
- GH₵0.86
- 52-week low
- GH₵0.05
- Avg volume (3M)
- —
- Shares outstanding
- 274.41M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.